Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael R Harrison

Showing results (171-180 of 183) with videos related to

Pageof 19
Sort By:
Clinical Genitourinary Cancer|August 8, 2021
A Prospective Multicenter Evaluation of Initial Treatment Choice in Metastatic Renal Cell Carcinoma Prior to the Immunotherapy Era: The MaRCC Registry ExperienceBrian A Costello, Nrupen A Bhavsar, Yousef Zakharia, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 3, 2020
Efficacy and Safety of Nivolumab Plus Ipilimumab versus Sunitinib in First-line Treatment of Patients with Advanced Sarcomatoid Renal Cell CarcinomaNizar M Tannir, Sabina Signoretti, Toni K Choueiri, et al.
Cancer|March 25, 2021
Active surveillance of metastatic renal cell carcinoma: Results from a prospective observational study (MaRCC)Michael R Harrison, Brian A Costello, Nrupen A Bhavsar, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 13, 2016
Immunomodulatory Activity of Nivolumab in Metastatic Renal Cell CarcinomaToni K Choueiri, Mayer N Fishman, Bernard Escudier, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|June 10, 2017
Kidney Cancer, Version 2.2017, NCCN Clinical Practice Guidelines in OncologyRobert J Motzer, Eric Jonasch, Neeraj Agarwal, et al.
JAMA Oncology|October 21, 2021
Clinical Activity and Safety of Cabozantinib for Brain Metastases in Patients With Renal Cell CarcinomaLaure Hirsch, Nieves Martinez Chanza, Subrina Farah, et al.
European Urology Open Science|December 22, 2021
Randomized Phase 2 Trial of Abiraterone Acetate Plus Prednisone, Degarelix, or the Combination in Men with Biochemically Recurrent Prostate Cancer After Radical ProstatectomyKaren A Autio, Emmanuel S Antonarakis, Tina M Mayer, et al.
Cancer|May 5, 2021
A prospective trial of abiraterone acetate plus prednisone in Black and White men with metastatic castrate-resistant prostate cancerDaniel J George, Susan Halabi, Elisabeth I Heath, et al.
American Journal of Obstetrics and Gynecology|October 2, 2007
A prospective, randomized, multicenter trial of amnioreduction vs selective fetoscopic laser photocoagulation for the treatment of severe twin-twin transfusion syndromeTimothy M Crombleholme, David Shera, Hanmin Lee, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|November 7, 2019
NCCN Guidelines Insights: Kidney Cancer, Version 2.2020Robert J Motzer, Eric Jonasch, M Dror Michaelson, et al.
Pageof 19

Showing results (171-180 of 183) with videos related to

Sort By:
Pageof 19
Clinical Genitourinary Cancer|August 8, 2021
A Prospective Multicenter Evaluation of Initial Treatment Choice in Metastatic Renal Cell Carcinoma Prior to the Immunotherapy Era: The MaRCC Registry ExperienceBrian A Costello, Nrupen A Bhavsar, Yousef Zakharia, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 3, 2020
Efficacy and Safety of Nivolumab Plus Ipilimumab versus Sunitinib in First-line Treatment of Patients with Advanced Sarcomatoid Renal Cell CarcinomaNizar M Tannir, Sabina Signoretti, Toni K Choueiri, et al.
Cancer|March 25, 2021
Active surveillance of metastatic renal cell carcinoma: Results from a prospective observational study (MaRCC)Michael R Harrison, Brian A Costello, Nrupen A Bhavsar, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 13, 2016
Immunomodulatory Activity of Nivolumab in Metastatic Renal Cell CarcinomaToni K Choueiri, Mayer N Fishman, Bernard Escudier, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|June 10, 2017
Kidney Cancer, Version 2.2017, NCCN Clinical Practice Guidelines in OncologyRobert J Motzer, Eric Jonasch, Neeraj Agarwal, et al.
JAMA Oncology|October 21, 2021
Clinical Activity and Safety of Cabozantinib for Brain Metastases in Patients With Renal Cell CarcinomaLaure Hirsch, Nieves Martinez Chanza, Subrina Farah, et al.
European Urology Open Science|December 22, 2021
Randomized Phase 2 Trial of Abiraterone Acetate Plus Prednisone, Degarelix, or the Combination in Men with Biochemically Recurrent Prostate Cancer After Radical ProstatectomyKaren A Autio, Emmanuel S Antonarakis, Tina M Mayer, et al.
Cancer|May 5, 2021
A prospective trial of abiraterone acetate plus prednisone in Black and White men with metastatic castrate-resistant prostate cancerDaniel J George, Susan Halabi, Elisabeth I Heath, et al.
American Journal of Obstetrics and Gynecology|October 2, 2007
A prospective, randomized, multicenter trial of amnioreduction vs selective fetoscopic laser photocoagulation for the treatment of severe twin-twin transfusion syndromeTimothy M Crombleholme, David Shera, Hanmin Lee, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|November 7, 2019
NCCN Guidelines Insights: Kidney Cancer, Version 2.2020Robert J Motzer, Eric Jonasch, M Dror Michaelson, et al.
Pageof 19